letrozole


Also found in: Medical, Wikipedia.

let·ro·zole

 (lĕt′rə-zōl′)
n.
A nonsteroidal drug, C17H11N5, that inhibits the enzyme aromatase and is used to treat breast cancer in postmenopausal women.

[le-, of unknown origin + alteration of triazole.]

letrozole

(ˈlɛtrəˌzəʊl)
n
(Pharmacology) an anti-oestrogen drug used in the treatment of breast cancer in post-menopausal women. Also called (trademark): Femara
References in periodicals archive ?
M2 PHARMA-December 7, 2017-Ibrance (palbociclib) plus Letrozole Improves Progression-Free Survival in ER+, HER2- Metastatic Breast Cancer
EU approval follows a positive opinion granted in June by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which was based on superior efficacy and demonstrated safety of Kisqali plus letrozole versus letrozole alone in the pivotal Phase III MONALEESA-2 trial.
It can be utilised in combination with letrozole, anastrozole or exemestane.
A February urine sample showed the athlete had the chemical letrozole in her system.
The 30-year-old Italian tested positive for the cancer treatment drug letrozole, which can increase body mass, in February following which the International Tennis Federation announced the suspension on Monday,
A sub-group analysis revealed that patients receiving r-FSH, rather than clomiphene or letrozole, had a significantly higher clinical pregnancy rate after r-hCG trigger as compared to the LH surge group (21.
Novartis has released the Kisqali Femara Co-Pack (ribociclib and letrozole tablets), a treatment for metastatic breast cancer in postmenopausal women, to U.
Overall survival data are immature but approval was based on improvement in progression-free survival (PFS) among 334 women randomized to receive ribociclib plus letrozole compared to 334 women randomized to receive placebo plus letrozole in phase III MONALEESA-2 (hazard ratio, 0.
Largest among the trials is an extended study that unequivocally demonstrates that 10 years of an aromatase inhibitor, letrozole, is superior to five years of letrozole therapy for preventing a recurrence of hormone receptor-positive (HR+) breast cancer.
In terms of improving the 5-year disease-free survival (DFS) rate, yes, according to results of a randomized study that compared extended letrozole treatment with placebo, in which the DFS rates were 95% and 91%, respectively.
Objective: To observe the protective effect of Nigella sativa on number of cystic follicles in Letrozole induced polycystic ovaries in mice.
sup][1] Vascular thrombotic events, such as acute myocardial infarction and acute cerebral infarction, in patients with breast cancer after initiation of letrozole therapy have been documented in the literature.